Phio Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
The discussion highlighted the successful phase I-B results for PH-762, the unique and versatile INTASYL platform, and robust manufacturing processes. Plans are underway for a new clinical trial next year, with ongoing efforts to secure funding and expand indications.
-
INTASYL technology enables precise, safe gene silencing for cancer immunotherapy, with PH-762 showing strong safety and efficacy in phase I-B trials for cutaneous squamous cell carcinoma. Commercial-scale production and a robust pipeline support future growth, with significant market potential and broad clinical applicability.
-
The discussion highlighted a novel siRNA-based therapy for skin cancer that targets PD-1 locally, showing promising safety and efficacy in early trials. The technology could reduce the need for invasive surgery and has potential applications in other cancers, with regulatory milestones and funding strategies outlined for the next year.
-
A novel RNA-based immunotherapy for skin cancer showed strong efficacy and safety in phase I-B trials, with plans to advance to phase II-B/III next year. The company is well-capitalized, focusing on high-value indications and out-licensing non-core assets.
-
A novel RNA-based therapy for skin cancer demonstrated strong efficacy and safety in early trials, with 85% response at the highest dose and no toxicities. The company is preparing for pivotal studies, has a robust IP portfolio, and is exploring partnerships for broader applications.